Index

  1. A

    1. Annual General Meeting
    2. Apprenticeship position
    3. Assets
    4. Auditor’s report

  2. B

    1. Balance Sheet
    2. BHQ880
    3. Business Development

  3. C

    1. Cash flows
    2. Cash flow statement
    3. Capital expenditure
    4. CD38
    5. Change of control
    6. Committees of the Supervisory Board
    7. Competition
    8. Convertible Bonds
    9. Corporate Communications
    10. Corporate Governance Report
    11. Corporate Social Responsibility
    12. Costs of goods sold
    13. Credit rating
    14. Currency risk

  4. D

    1. Declaration of conformity
    2. Declarations persuant to § 315
    3. para 4 of the German Commercial
    4. Code (HGB)
    5. Directors’ dealings
    6. Dividend

  5. E

    1. Earnings per share
    2. EBIT
    3. Employees
    4. Environmental protection
    5. Equity

  6. F

    1. Financial analysis
    2. Financial calendar 2010
    3. Forecast

  7. G

    1. Gantenerumab
    2. GM-CSF
    3. Goodwill

  8. H

    1. Human resources

  9. I

    1. Income taxes
    2. Information required under takeover law
    3. Intellectual property
    4. ISO-Certificates

  10. K

    1. Key figures

  11. L

    1. Letter to the Shareholders
    2. Liabilities
    3. Liquidity

  12. M

    1. Management Board
    2. Management of the Group
    3. Management report
    4. Manufacturing license
    5. Market capitalization
    6. Milestone payments
    7. MOR103
    8. MOR202

  13. N

    1. Net income
    2. Non-operating items

  14. O

    1. Operating expenses
    2. Operating leases
    3. Operating profit
    4. Opportunities
    5. Outlook

  15. P

    1. Patents
    2. Pension
    3. Personnel cost
    4. Procurement
    5. Production
    6. Proprietary pipeline
    7. Provisions

  16. Q

    1. Quality assurance
    2. Quality management

  17. R

    1. R1450
    2. Remuneration report
    3. Remuneration, Supervisory Board
    4. Remuneration, equity-based
    5. Remuneration, Management Board
    6. Report of the Supervisory Board
    7. Research and development
    8. Research and development expenses
    9. Research Antibodies
    10. Responsibility statement
    11. Revenues
    12. Revenue recognition
    13. Risks
    14. Risk management

  18. S

    1. Sales, general and administrative expenses
    2. Segment reporting
    3. Segment Research Antibodies
    4. Segment Therapeutic Antibodies
    5. Shareholder structure
    6. Shareholdings, Management and Supervisory Boards
    7. Share price development
    8. Share, repurchase
    9. Social Responsibility
    10. Statement of operations
    11. Statements of changes in shareholders’ equity
    12. Stock-based compensation
    13. Stock options
    14. Subsequent events
    15. Subsidiaries
    16. Supervisory Board
    17. Sustainability

  19. T

    1. Taxes
    2. Trading volumes
    3. Training

  20. V

    1. VorstAG

  21. W

    1. WACC